Zdrowie i gospodarka · 22/10/2021

FDA Clears ROBAXIN and ROBAXIN-750 for Continued Sale

The US Food and Drug Administration (FDA) has officially determined that the methocarbamol-based medications ROBAXIN and ROBAXIN-750, available in 500mg and 750mg oral tablet forms, were not withdrawn from the market due to safety or efficacy concerns, allowing the FDA to continue approving abbreviated new drug applications (ANDAs) for these products as long as they meet regulatory requirements.